Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

622
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
622
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

392
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
392
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design, simulate, refine: simulation-guided clinical trials for accelerated drug development.

Nature reviews. Drug discovery·2026
Same author

Type 2 diabetes risk alleles in peptidyl-glycine alpha-amidating monooxygenase influence GLP-1 levels and response to GLP-1 receptor agonists.

Genome medicine·2026
Same author

Clinical trials with interim analyses: standardizing terminology to increase clarity.

Trials·2025
Same author

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial.

Statistics in medicine·2025
Same author

Monitoring overall survival in pivotal trials in indolent cancers.

Statistics in biopharmaceutical research·2025
Same author

RMST for Interval-Censored Data in Oncology Clinical Trials.

Statistics in medicine·2025

Related Experiment Video

Updated: Apr 22, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.3K

Optimizing the data combination rule for seamless phase II/III clinical trials.

Lisa V Hampson1, Christopher Jennison

  • 1Medical and Pharmaceutical Statistics Research Unit, Department of Mathematics and Statistics, Lancaster University, Lancaster, U.K.

Statistics in Medicine
|October 16, 2014
PubMed
Summary

Seamless phase II/III clinical trials can improve power by using data from both phases. Optimal decision rules for the final hypothesis test balance phase II and III data, enhancing treatment superiority demonstration.

Keywords:
Bayes decision problemclosed testing procedurecombination testmultiple hypothesis testingseamless phase II/III trialtreatment selection

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Related Experiment Videos

Last Updated: Apr 22, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

3.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmaceutical Research

Background:

  • Seamless phase II/III clinical trials integrate early-stage findings into later stages.
  • Optimizing the use of data from both phases is crucial for statistical power and efficiency.
  • Controlling the familywise type I error rate is essential when combining data from multiple trial phases.

Purpose of the Study:

  • To evaluate the impact of different hypothesis testing methods on the power of seamless phase II/III trials.
  • To derive optimal decision rules for selecting and testing treatments in a seamless design.
  • To determine the optimal allocation of sample size between phase II and phase III.

Main Methods:

  • Derivation of decision rules maximizing power, framed as a multivariate Bayes decision problem.
  • Development of a closed testing procedure using inverse normal combination and Dunnett tests.
  • Analysis of a weighted average approach combining phase II and phase III data for the selected treatment.
  • Optimization of sample size distribution between phase II and phase III for the weighted average rule.

Main Results:

  • The choice of hypothesis testing method significantly impacts the power to detect treatment superiority.
  • Two robust and efficient decision rules were identified: a weighted average rule and a closed testing procedure.
  • Optimal sample size allocation for the weighted average rule was determined.
  • Incorporating phase II data can substantially increase power, often requiring 50-70% of the phase II sample size to be added to phase III.

Conclusions:

  • Strategic use of phase II data in the final analysis of seamless trials can enhance statistical power.
  • The identified decision rules offer efficient methods for hypothesis testing in integrated trial designs.
  • Optimal sample size allocation is key to maximizing the benefits of seamless phase II/III trials.
  • These findings provide valuable guidance for designing more powerful and efficient clinical trials.